Transgenic Chicken Approved to Treat Rare Genetic Disease

Posted by Caroline on December 17th, 2015


Following the transgenic goats and transgenic rabbits, transgenic chicken were approved on the 8th, Dec. By the FDA to join the pharmacy team. Eggs of this kind of chicken contain a project enzyme that can be used to produce drug Kanuma-to treat rare genetic diseases. This drug, also, became one of the few produced by transgenic biopharmaceutical products in the US market.


According to the report of Nature, Kanuma is the symptomatic drugs of LaL-D. It was given the right of priority review for it being orphan drugs (referring to drugs used for prevention, treatment and diagnosis of rare disease). LaL-D can lead the accumulation of fat in the patients’ live, spleen and vessels. Infants with this disease often suffer from rapid collapse and elderly patients would suffer from enlargement, fibrosis and cirrhosis of liver and cardiovascular disease.


Since every cell of the transgenic chicken contains the engineered DNA, FDA identify this kind of genetic modification as a new animal drug. In the review process, FDA investigated lots of issues like: whether the DNA modification will hurt the chicken or not, and whether the situation is stable or not after the modified DNA is passed to the next generation.


Different from the salmon approved by FDA last month for human consumption, this kind of transgenic chicken will not enter the food supply chain. FDA said, those chickens are housed indoors and even unexpected entering into the food supply chain or the possibility of an adverse impact on the environment is unlikely.


In 2009, anticoagulants Atryn produced from GM goat milk were approved to market. Last year, medicine for the treatment of hereditary angioedema produced from transgenic rabbit was also recognized by the institution.

Like it? Share it!


Caroline

About the Author

Caroline
Joined: December 17th, 2015
Articles Posted: 60

More by this author